Clinical trial / 2020
Single oral administration of up to 500 mg NMN was safe and effectively metabolized without significant deleterious effects in healthy men.
Ten healthy men received single oral doses of 100, 250, and 500 mg nicotinamide mononucleotide (NMN), with clinical parameters and NMN metabolite pharmacokinetics monitored for 5 hours after each intervention. The single oral doses caused no significant clinical symptoms or changes in heart rate, blood pressure, oxygen saturation, body temperature, ophthalmic examination, or sleep quality. Laboratory analyses showed increases in serum bilirubin and decreases in serum creatinine, chloride, and blood glucose within normal ranges, independent of dose. Plasma concentrations of N-methyl-2-pyridone-5-carboxamide and N-methyl-4-pyridone-5-carboxamide increased significantly in a dose-dependent manner.
- Study type
- Single-arm non-randomized trial
- Who was studied
- 10 healthy men
- What was measured
- Safety, clinical parameters, ophthalmic exam, sleep quality, and pharmacokinetics of NMN metabolites
THE PAPER
Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men.
Irie J, Inagaki E, Fujita M, Nakaya H, Mitsuishi M, Yamaguchi S, Yamashita K, Shigaki S, Ono T, Yukioka H, Okano H, Nabeshima YI, Imai SI, Yasui M, Tsubota K, Itoh H. Endocr J, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.